Latest advanced Therapies
BeNeLuxA initiative supports the reimbursement of Zolgensma® in Belgium, Ireland and the Netherlands

Yasmina Zegaoui, Consultant at Lightning Health, looks at how this managed entry agreement initiative can enable the reimbursement of a much-needed therapy for patients

ATMP market access: Advanced Therapies Congress & Expo 2021

Yasmina Zegaoui, Senior Consultant and Nasos Kipentzoglou, Senior Analyst at Lightning Health report on some of the key topics from the two-day event

Thinking Outside the Box: Sustainable Solutions to Drive Global Patient Access for Advanced Therapy Medicinal Products (ATMPs)

Lightning Health’s thought-leadership perspective on sustainable solutions to drive global patient access for ATMPs

ATMP Market Access: ensuring sustainable patient access to life-changing therapies

How Lightning Health can support you to navigate your access challenges associated with ATMPs

Retrospective analysis of NICE CAR-T therapy single technology appraisals and identification of strategies to minimise time to patient access

In this article, our colleagues Eleanor Butler and Nancy Cross carry out a retrospective review of the NICE CAR-T therapy single technology appraisals

The G-BA implements post launch real world evidence generation for Zolgensma®

Nasos Kipentzoglou, Analyst and Eleanor Butler, Consultant at Lightning Health review the recent approach that the G-BA has taken in requiring the mandatory collection of real world evidence for Zolgensma®

NICE rejects gene therapy Zynteglo

Following NICE draft guidance rejecting Zynteglo, Eleanor Butler, Consultant at Lightning Health explores why the beta thalassaemia treatment is not recommend for routine NHS funding